In this article, we will discuss Belzutifan (Dosage Overview). So, let’s get started.
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
The recommended dosage of Belzutifan is 120 mg administered orally once daily until disease progression or unacceptable toxicity. Belzutifan should be taken at the same time each day and may be taken with or without food. Advise patients to swallow tablets whole. Do not chew, crush, or split Belzutifan prior to swallowing. If a dose of Belzutifan is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for Belzutifan the next day. Do not take extra tablets to make up for the missed dose. If vomiting occurs any time after taking Belzutifan, do not retake the dose. Take the next dose on the next day.